Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
ACE Report #59
Ace Report Cover Foot & Ankle

rhPDGF-BB (Augment) is a safe alternative to autologous graft in foot and ankle fusion

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Prospective, Randomized, Multi-Center Feasibility Trial of rhPDGF-BB Versus Autologous Bone Graft in a Foot and Ankle Fusion Model

Foot Ankle Int. 2011 Apr;32(4):344-54.

Contributing Authors: CW Digiovanni J Baumhauer SS Lin WS Berberian AS Flemister MJ Enna P Evangelista J Newman

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


20 patients requiring hindfoot fusion were randomized to receive either a biosynthetic bone graft substitute (Augment Bone Graft, a recombinant form of platelet-derived growth factor (rhPDGF-BB)) or an autologous bone graft (ABG), in order to compare safety and efficacy between the two graft types. The results of this study suggest the biosynthetic bone graft is a safe and efficacious alternative ...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.